Business
Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds
- Paving the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress - NAPLES, Fla., Oct. 5, 2021
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"- Paving the way to select lead drug candidates for preclinical studies to support clinical evaluation in cancer-related distress -\n\n\nNAPLES, Fla., Oct. 5, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) (\"Enveric\" or the \"Company\"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that PsyAITM – an artificial intelligence tool designed by April19 to provide comprehensive pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies – has successfully identified viable psychedelic molecules for further drug discovery from Enveric's initial list of 500 psychedelic molecular compounds within its \"Psybrary.\"\nPsyAI has accelerated the development of optimized pharmaceutical candidates, each tailored specifically for difficult-to-treat mental health indications. Enveric believes it will be the first psychedelic drug discovery and development company to employ this machine-learning technology against an extensive psychedelic molecule library to evaluate higher-likelihood molecules that treat conditions that include cancer-related distress, PTSD, and other central nervous system (CNS) indications.\nEnveric's adoption of PsyAI technology, which utilizes a set of machine-learning models and other computational techniques, including 3D structure generation and docking, is expected to result in predictive outputs on relative drug potential from Enveric's \"Psybrary\" of known and novel compounds. Enveric intends to use the results in predicting drug likeness, CNS exposure, oral bioavailability, toxicity, serotonin 5HT-2A receptor affinity and activity. The Company expects to combine the predictions into a multi-parameter score to rank the compounds by desirability and patentability on a comparative basis to a dataset of FDA-approved, orally available CNS drugs.\nAdditionally, this technology has helped Enveric identify clusters of compounds that are likely to undergo metabolic conversion into promising active compounds within the human body, therefore acting as prodrugs. Further analysis and examination of these prodrugs, also known as Generation 2 psychedelics, may expand the scope of the \"Psybrary\" and offer possible ways ...